All information provided in Connect is for information purposes only and does not constitute a legal relationship between Redox and any organization or entity unless otherwise specified.
Madrigal Pharmaceuticals
Overview
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Find out more about Madrigal Pharmaceuticals
Curious how you'd connect to a healthcare product like Madrigal Pharmaceuticals?
Pharma & biotech
Pharma and biotech companies are improving patient safety and reducing medication errors by ensuring relevant patient information is available to all healthcare providers. Explore the industry leaders powered by Redox.
Explore all Pharma & biotech powered by Redox
Can’t find what you’re looking for?
The information about healthcare organizations contained within this directory, including their names, websites, and descriptions, was accurate to the best of Redox’s knowledge as of the date of posting. Redox disclaims all warranties and representations, express or implied, regarding the information and services listed in this directory. Redox does not guarantee the accuracy of the information, nor does it endorse or recommend any particular provider or service. Users of this directory are solely responsible for verifying the accuracy and suitability of any information or service before relying on it.
